PlasmidInfo:
PlasmidInformation
ProductName:pSF-CMV-Puro-COOH-3C-T7
ProductCode:OG1152
Size(bp):6207bp
BacterialAntibioticSelection:KanR
OriginandCompatibility:pUChighcopyderivedfrompBR322
BacterialCopyNumber:500-700percell
Promoter:Cytomegalovirus(CMV)immediateearlypromoter/HumanUbiquitinPromoter
PlasmidPurpose:
Thisplasmidisdesignedtoexpresstaggedproteinsinmammaliancellseitherbytransienttransfectionorbycreatingstablecelllines.ItcontainsapuromycinresistanceexpressioncassetteusingthehumanUbiquitinpromotertodriveexpressionandallowfortheselectionofcellscontainingtheplasmid.
AbouttheCleavageTag:Thisplasmidalsoencodesaproteasecleavagesitethatisdesignedtobepositionedbetweenyourgeneofinterestandthetagtoallowtheremovalofthetagfollowingproteinpurificationorisolation.Thisplasmidcontainsa3Ccleavagetag.Theproteinsequenceofthecleavagetagis:LEVLFQ?GP.HumanRhinovirus(HRV)3CProteaseisahighlyspecificproteasethatcleavesbetweentheGluandGlyresiduesofitsrecognitionsite.Itisoftenproducedwiththetrademname"PreScissionprotease".
Formoreinformationonwhichcleavagetagtouseseeourcleavagetagguide.
PromoterExpressionLevel:ThisplasmidcontainsthemammalianCMVpromotertodrivegeneexpression.WehavetestedallofourmammalianpromotersinarangeofcelltypesandCMVisconsistentlythestrongestinthosewehavestudied.HowevertherearemanyreportsoftheCMVpromoterdemonstratingsilencingbymethylationinlong-termculture.ForthisreasonwestockarangeofotherpromotersthatarecompatIBLewiththisplasmidandareavailableonrequest.
Thisplasmidcontainsac-terminalT7epitopetagthatcanbefusedtoageneofinteresttoallowproteindetectionand/orpurification.Thesequenceofthetagis:MASMTGGQQMG
Formoreinformationonthemethodsthatcanbeusedtopurifyproteinspleaseseeourproteintagguide.
SequenceandMap:
OtherInfo:
TranscriptionTermination:Thisplasmidcontainsthreealternativetranscriptionterminatorsformammalianbacterialandbacteriophage(T7)expression.Thismeansthatonlythepromoterneedstobechangedtoaltertheexpressionsystemyouareusing.Wesellmultiplepromotersthatcanbeusedineachofthesesystems.Thepresenceofeachterminatordoesnotreduceexpressioninthealternativesystems.
Cloning:
MakingProteinFusions:ThisplasmidhasbeendesignedtoallowthreetypesofcloningintothemainMCStojoinacodingsequencewiththetag.
SnapFusionCloning:IfyouwouldliketofuseyourcodingsequencetothetagwithminimaladditionalbasesyoucanuseourSnapFusiontechnology.ThisprocessinvolvesamplifyingyourgenebyPCRtoaddspecificrestrictionsitesontotheends.WhenthesesitesarecuttheyproduceanoverhangthatiscompatiblewiththisplasmidcutwithBseRIorBsgI.
Toinsertyourgene:
1:Amplifyyourgenewithprimersdesignedusingthisspreadsheet
2:CuttheplasmidwitheitherBseRIorBsgI.*
3:Cutyourgenewiththeenzymeyouaddedusingthespreadsheet(anyofAcuIBpmIBpuEIBseRIBsgIEciI).
4:ClonethegeneintotheplasmidusingDNAligase.
UsingthismethodwithanN-terminaltagplasmidwillresultinthetagcodingsequenceimmediatelyfollowedbyyourgenesATGstartcodonatthejoin.Thisresultsinaseamlessfusionofthetwosequenceswithnoextrabasesbeingadded.UsingthismethodonC-terminaltagplasmidswillconvertyourgenesstopcodonintoaTAC(TyrY)codonfollowedbytheplasmidtagcodingsequence.Thisresultsinnoextrabasesbetweenyourgeneandthetag.Seethediagrambelowformoreinformation.
*PleasenotethatinsectexpressionplasmidscannotbecutwithBsgIonlyBseRIbecauseofunavoidableconflictingsitesinthebackbone.AlsoYeastplasmidscanonlybecutwithBsgInotBseRIbecauseofconflictingsitesinthebackbone.
Usingthistechniquewillcreateagenefragmentthatcanbeligatedintoanyorour>1500peptideandreportertagplasmids.Ifyouuseoneoftheothertechniquesbelow(GibsonInFusionSeamlessorLIC)youwillneednewprimersforeveryvectoryoucloneintobecausethearmsofhomologywillchangeaccordingtothetagplasmidyouarecloninginto.
Ifyoufindthatyourgenesequencehassitesinitthatmakeusingthiscloningstrategydifficultyoucanstilluseoneofthealternativemethodsbelow(e.g.standardcloningorGibsoncloning).
OpenthePrimerDesignTooltohelpyoudesignprimersforcloningyourgeneinourSnapFusiontechnique.
StandardEnzymes:Ifyouarenotconcernedaboutleavingafewextrabasesbetweenthetagcodingsequenceandyourgeneyoucancloneyourgeneintothevectorusingstandardcloningrestrictionenzymes.Thisstrategywillrequireyoutochoosewhichenzymesyouwanttousetocloneyourgene.
OpenthePrimerDesignToolwhichprovidesprimerswithdifferentenzymechoicespositioningyourgeneasclosetothetagaspossibleineachcase.Pleasenotethatstandardenzymeswillalwaysleaveadditionalnucleotidesbetweenyourgeneandthetagbutusingthespreadsheetwillensurethetagandgeneareinframe.
Gibsoncloning/InfusionHD/GeneArtSeamless/LigaseIndependentCloning(LIC)Methods:ThesecloningtechniquesusereagentssoldbyothercompaniesandallowyoutofusesequencestogetherusingenzymesthatchewbacktheDNAtoleaveoverlappingends/overhangs.ThesubsequentmethodofjoiningtheDNAdependsonthekitused.Touseoneofthesetechniquesyoucaneitherdesignyourownprimersoryoucanusethespreadsheetbelowtohelpwiththedesign.
OpenthePrimerDesignTooltohelpyoudesignprimersforcloningyourgeneusingGibsonassemblyInfusionHDGeneArtSeamlesscloningorLigaseIndependentCloning(LIC)techniques.
IPStatus:
IntellectualPropertyStatusThisproductispartofourSnapFastplasmidrange,formoreinformationontheIntellectualpropertystatusofthisplasmidpleaseclickhere
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
(forced expression)或过表达(overexpression),以观察基因表型,反义则是用来抑制基因表达,以观察在目的基因的表达受到抑制的情况下表型的变化
我现在手上有PMD2.G与PSPAX2两个载体，求推荐与其配套的慢病毒过表达载体，谢谢。
常用细菌质粒进行构建，构建过程中运用限制性核酸内切酶切割出与目的基因相合的末端（多为黏性末端，也有平末端），采用DNA连接酶连接，导入生物体实现表达。标记基因可帮助识别质粒并检测是否成功整合到染色体DNA中。
表达载体（Expression vectors）就是在克隆载体基本骨架的基础上增加表达元件（如启动子、RBS、终止子等），使目的基因能够表达的载体。如表达载体pKK223-3是一个具有典型表达结构的大肠杆菌表达载体。其基本骨架为来自pBR322和pUC的质粒复制起点和氨苄青霉素抗性基因。在表达元件中，有一个杂合tac强启动子和终止子，在启动子下游有RBS位点（如果利用这个位点，要求与ATG之间间隔5-13bp），其后的多克隆位点可装载要表达的目标基因。
常用细菌质粒进行构建，构建过程中运用限制性核酸内切酶切割出与目的基因相合的末端(多为黏性末端，也有平末端)，采用DNA连接酶连接，导入生物体实现表达。标记基因可帮助识别质粒并检测是否成功整合到染色体DNA中。
表达载体(Expression vectors)就是在克隆载体基本骨架的基础上增加表达元件(如启动子、RBS、终止子等)，使目的基因能够表达的载体。如表达载体pKK223-3是一个具有典型表达结构的大肠杆菌表达载体。其基本骨架为来自pBR322和pUC的质粒复制起点和氨苄青霉素抗性基因。在表达元件中，有一个杂合tac强启动子和终止子，在启动子下游有RBS位点(如果利用这个位点，要求与ATG之间间隔5-13bp)，其后的多克隆位点可装载要表达的目标基因。
各位好，最近构建慢病毒沉默载体，问题是提完质粒酶切验证是阳性，但是测序检测不到插进去的shRNA，已经重复连接转化多次，依旧没有得到阳性质粒，请大神帮忙分析下原因，感谢！！
问题
1AmpR是在筛选阳性质粒时发挥作用；
2氨卞青霉素只对原核生物起作用；
3在病毒颗粒感染目的细胞后，AmpR并未在目的细胞中表达（或者说没整合入目的细胞基因组）
4如果有整合入目的细胞基因组，那么可以起到药物筛选的作用吗？
慢病毒系统构建.doc(182.0k)
暂无品牌分类
